Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Ex-Bard execs' trial

This article was originally published in The Gray Sheet

Executive Summary

Ex-Bard execs' trial: Jury deliberation in the conspiracy case against five former Bard officials begins Aug. 17. The five remaining defendants in the trial -- former Bard CEO George Maloney, former Bard Group Vice President David Prigmore, former USCI President John Cvinar, former USCI Director of Regulatory Affairs and Quality Assurance Lee Leichter and former USCI Director of Regulatory Affairs Kenneth Thurston -- are facing criminal conspiracy charges related to alleged actions such as failing to make needed premarket filings to FDA, lying to the agency in the course of obtaining device approvals and failing to report injuries resulting from product failures. Closing arguments in the case were presented Aug. 15-16. The ex-Bard officials' lawyers rested their case without presenting a defense ("The Gray Sheet" Aug. 14, p. 33)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT004562

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel